Therefore, heterozygous carriers require a dosage adjustment, whereas homozygous carriers should not take 6MP for treatment because the somatic NUDT15 deletion in tumor cells can acquire no additional 6MP‐related toxicity. Here, NUDT15 is linked to neoplasm.